Clinical Trial Detail

NCT ID NCT04139434
Title Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Newave Pharmaceutical Inc
Indications

acute myeloid leukemia

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

LP-108

Age Groups: adult senior

No variant requirements are available.